DDInter1679 DDInter704
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Sitagliptin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) PTPN1
PTPN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Sitagliptin {u} (Compound) upregulates {v} (Gene) PIGB
PIGB {u} (Gene) is downregulated by {v} (Compound) Everolimus
Sitagliptin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Sitagliptin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) PTPN1
PTPN1 {u} (Gene) is regulated by {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Everolimus
Sitagliptin {u} (Compound) downregulates {v} (Gene) ALAS1
ALAS1 {u} (Gene) is downregulated by {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Sitagliptin {u} (Compound) upregulates {v} (Gene) PIGB
PIGB {u} (Gene) regulates {v} (Gene) TBPL1
TBPL1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Sitagliptin (Compound) downregulates PTPN1 (Gene) and PTPN1 (Gene) is upregulated by Everolimus (Compound)
Sitagliptin (Compound) upregulates PIGB (Gene) and PIGB (Gene) is downregulated by Everolimus (Compound)
Sitagliptin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Sitagliptin (Compound) downregulates PTPN1 (Gene) and PTPN1 (Gene) is regulated by MTOR (Gene) and MTOR (Gene) is bound by Everolimus (Compound)
Sitagliptin (Compound) downregulates ALAS1 (Gene) and ALAS1 (Gene) is downregulated by kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound)
Sitagliptin (Compound) upregulates PIGB (Gene) and PIGB (Gene) regulates TBPL1 (Gene) and TBPL1 (Gene) is upregulated by Everolimus (Compound)